Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn's Disease

被引：0
|
作者：
Chua, L. [1 ]
Otani, Y. [1 ]
Friedrich, S. [1 ]
Durand, F. [1 ]
Zhang, X. [1 ]
机构：
[1] Eli Lilly & Co, Immunol, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1044
引用
收藏
页码：I1873 / I1873
页数：1
相关论文
共 50 条
  • [21] Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Liao, Sam
    Strauss, Richard
    Reinisch, Walter
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 157 - 174
  • [22] Improvement in fatigue with mirikizumab therapy is associated with clinical remission and pain improvements but not with endoscopic response in patients with moderately to severely active Crohn's disease
    Reguiero, Miguel
    Fischer, Monika
    Rubin, David T.
    Hibi, Toshifumi
    Bossuyt, Peter
    Juillerat, Pascal
    Pollack, Paul
    Zhou, Xian
    Protic, Marijana
    Hunter, Theresa
    Chan, Lai Shan
    Cartier, Hilde
    Hindryckx, Pieter
    SWISS MEDICAL WEEKLY, 2023, 153 : 27S - 27S
  • [23] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
    Sandborn, W. J.
    Sands, B.
    Kobayashi, T.
    Tuttle, J.
    Schmitz, J.
    Durante, M.
    Higgs, R.
    Canavan, J. B.
    Siegel, R.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60
  • [24] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis
    Xu, Yan
    Hu, Chuanpu
    Chen, Yang
    Miao, Xin
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Sharma, Amarnath
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 889 - 902
  • [25] Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Kassir, Nastya
    Zhu, Rui
    Moein, Anita
    Langenhorst, Jurgen
    Ribbing, Jakob
    Zhang, Rong
    Tang, Meina T.
    Oh, Young S.
    Zhang, Wenhui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1234 - 1243
  • [26] Population pharmacokinetics and exposure-response of filgotinib in patients with moderate to severe Crohn's disease
    Sharma, Shringi
    Xin, Yan
    Gao, Yuying
    Namour, Florence
    Mathias, Anita
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S36 - S36
  • [27] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis
    Xu, Yan
    Adedokun, Omoniyi J.
    Chan, Daphne
    Hu, Chuanpu
    Xu, Zhenhua
    Strauss, Richard S.
    Hyams, Jeffrey S.
    Turner, Dan
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 590 - 604
  • [28] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023, : 1479 - 1491
  • [29] Unemployment and disability in patients with moderately to severely active Crohn's disease
    Feagan, BG
    Bala, M
    Yan, S
    Olson, A
    Hanauer, S
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (05) : 390 - 395
  • [30] Improvement in Fatigue With Mirikizumab Therapy Is Associated With Clinical Remission and Pain Improvements but Not With Endoscopic Response in Patients With Moderately-to-Severely Active Crohn's Disease
    Regueiro, Miguel
    Fischer, Monika
    Rubin, David T.
    Hibi, Toshifumi
    Bossuyt, Peter
    Juillerat, Pascal
    Pollack, Paul
    Zhou, Xian
    Protic, Marijana
    Gibble, Theresa Hunter
    Chan, Lai-Shan
    Carlier, Hilde
    Hindryckx, Pieter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S602 - S603
12345